Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344670 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL84710 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL10585294 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL12585497 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943562 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL4370045 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943561 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL5870038 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300984 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300985 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775348-A | Preparation method of polypeptide Angstrom Pi Dalong acetate | 深圳市第二人民医院(深圳市转化医学研究院) | 2025-04-08 | — | — | CN | claimed |
| CN-119431221-A | Synthesis method of chiral intermediate of gemagliptin | 安徽峆一药业股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-115787325-B | Polyester low-temperature dyeing promoter and preparation method thereof | 太仓宝霓实业有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-111825742-B | Polypeptide solid phase synthesis of CTPA as special coupling agent for amino acid ionic liquid | 陈铭 | 2024-01-30 | — | — | CN | claimed |
| CN-115787325-A | Polyester low-temperature dyeing accelerant and preparation method thereof | 太仓宝霓实业有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115490684-A | 3S-1,2,3, 4-tetrahydro-beta-carboline-3-methyl-amino acid, preparation thereof, antithrombotic activity and application thereof | 首都医科大学 | 2022-12-20 | — | — | CN | claimed |
| CN-115477648-A | Carboline derivative, preparation method thereof and application thereof in preparing antitumor drugs | 首都医科大学 | 2022-12-16 | — | — | CN | claimed |
| CN-102796169-B | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-01-29 | — | — | CN | claimed |
| CN-102796169-A | Double saturated aliphatic chain alcohol Glu-Asp-Gly-Asp tetrapeptide esters and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-11-28 | — | — | CN | claimed |
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4729561-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-4629736-A | HIGH FIBRINOLYTIC ACTION; WATER SOLUBILITY; ANTICOAGULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-16 | — | — | US | disclosed |
| US-4600705-A | Gonadoliberin derivatives containing a β-aspartyl group, a process for the preparation thereof and pharmaceutical preparations containing them | Richter Gedeon Veyteszeti Gyar R.T. (HU) | 1986-07-15 | — | — | US | disclosed |
| US-4529549-A | Compound containing guanidine and amino groups | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0136879-A2 | Fatty acid derivatives and processes of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
| EP-0105193-A2 | Spergualin-related compounds, processes for the preparation thereof and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | PPARA 1053/4885KLK5 2592/4885KLK7 2792/4885 |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, CALCB, SPPL2B | PPARA 3535/4885KLK5 1413/4885KLK7 678/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | PPARA 4569/4885KLK5 3192/4885KLK7 2129/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | PPARA 2297/4885KLK5 4629/4885KLK7 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.